
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem Inc. is advancing its late-stage development of novel anticancer agents, with promising data from the FRAME and RAMP 201 trials indicating improved efficacy and safety in cancer treatments, particularly for KRAS mutant low-grade serous ovarian cancer (LGSOC) and non-small cell lung cancer (NSCLC). The company anticipates significant revenue potential, estimating over $400 million in global sales for LGSOC and $200 million for NSCLC starting as early as mid-2025, contributing to a strengthened outlook following recent management discussions. Positive changes in operational focus, strong near-term visibility, and potential competitive positioning in the G12D inhibitor market further support the optimism surrounding Verastem's future performance.
Bears say
Verastem Inc's stock faces significant downside risks primarily due to the lack of substantial and definitive randomized data for its lead asset, avutometinib, which raises concerns about its efficacy and safety in clinical trials. Additionally, competitive pressures may adversely impact patient enrollment and market uptake, while the targeted nature of their treatments could restrict the initial market opportunity due to a limited addressable population. Furthermore, if the clinical development program fails to progress adequately, shares could potentially revert to a valuation aligned with the company's net cash position, indicating a bleak financial outlook for investors.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares